Congo-Kinshasa: EU Approval of First Ebola Vaccine is Game Changer

[VOA] This week the European Commission gave approval to a Ebola vaccine -- an act that the World Health Organization calls landmark moment for global health and a likely game-changer in the battle against this deadly disease.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

The Democratic Republic of the Congo (DRC) has seen an increase in the number of reported cases of the deadly haemorrhagic virus Ebola linked to ongoing violence by armed groups targeting remote communities, the World Health Organization (WHO) said on Friday. 
Source: UN News Centre - Health, Poverty, Food Security - Category: International Medicine & Public Health Source Type: news
by Kai J. Rogers, Bethany Brunton, Laura Mallinger, Dana Bohan, Kristina M. Sevcik, Jing Chen, Natalie Ruggio, Wendy Maury BackgroundEbolavirus (EBOV) outbreaks, while sporadic, cause tremendous morbidity and mortality. No therapeutics or vaccines are currently licensed; however, a vaccine has shown promise in clinical trials. A critical step towards development of effective therapeutics is a better understanding of factors that govern host susceptibility to this pathogen. As macrophages are an important cell population targeted during virus replication, we explore the effect of cytokine polarization on macrophage infectio...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Swati Gupta ’97 M.P.H. and Anant Shah ’07 M.P.H. are at the forefront of the global fight against Ebola.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the b...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
[New Times] Rwanda and the Democratic Republic of the Congo Sunday unveiled a massive vaccination campaign against Ebola Virus Disease (EVD) for their residents who live within the vicinity of a possible Ebola outbreak.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Up to 200,000 Regimens of Janssen ’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
- A stockpile of 500,000 doses of Ebola vaccine for emergency use in outbreaks of the deadly fever is being established by the global vaccine alliance GAVI.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Vaccine alliance announces creation of Ebola vaccine stockpile of about 500,000 doses
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
[WHO] Kinshasa, 5 December 2019 - Around 2.2 million children are to be vaccinated against measles in North Kivu, the Democratic Republic of the Congo (DRC), where efforts are underway to curb the world's second-worst Ebola outbreak amid persistent insecurity.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. PMID: 31787811 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
More News: African Health | Congo Health | Ebola | Ebola Vaccine | International Medicine & Public Health | Vaccines | WHO